Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

NCT07002320 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

78

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

Interventions

DRUG: SX-682
DRUG: Apalutamide

Sponsor

Institute of Cancer Research, United Kingdom

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]